PureTech Health: Announcement of Half-Year Results

About PureTech Health
PureTech is a clinical-stage biotherapeutics company focused on bringing to life novel classes of medicines to transform the lives of patients with devastating diseases. The Company has developed a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders fostered both internally and through its Founded Entities. PureTech’s R&D engine has resulted in the development of 29 therapeutic agents and therapeutic candidates, including two that have received both U.S. FDA approval and European Marketing Authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities across various indications and stages of clinical development, including registrational support studies. All of the underlying programs and platforms that led to this pipeline of therapeutic candidates were initially identified or discovered and subsequently advanced through key validation points by the PureTech team.

For more information, please visit www.puretechhealth.com or contact us at X (formerly Twitter) @puretechh.

Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that do not relate to historical facts should be deemed to be forward-looking statements, including, but not limited to, those regarding PureTech’s development plans and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that may cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2023 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the Company’s current and future business strategies and the environment in which it will operate in the future. Each forward-looking statement speaks only as of the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

View the source version on businesswire.com: https://www.businesswire.com/news/home/20240820540519/en/

The PureTech Health share at the time of publication of the news with an increase of 0.00 % until 19.00EUR
on the Frankfurt Stock Exchange (August 20, 2024, 8:10 a.m.).